These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 3135814)

  • 1. Effects of CS-514 on plasma lipids and lipoprotein composition in hypercholesterolemic subjects.
    Yoshino G; Kazumi T; Iwai M; Iwatani I; Matsuba K; Kasama T; Matsushita M; Otsuki M; Baba S
    Atherosclerosis; 1988 Jun; 71(2-3):95-101. PubMed ID: 3135814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of CS-514 on serum lipoprotein lipid and apolipoprotein levels in patients with familial hypercholesterolemia.
    Mabuchi H; Kamon N; Fujita H; Michishita I; Takeda M; Kajinami K; Itoh H; Wakasugi T; Takeda R
    Metabolism; 1987 May; 36(5):475-9. PubMed ID: 3106756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of CS-514 (eptastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum lipid and apolipoprotein levels in heterozygous familial hypercholesterolemic patients treated by low density lipoprotein (LDL)-apheresis.
    Mabuchi H; Fujita H; Michishita I; Takeda M; Kajinami K; Koizumi J; Takeda R; Takegoshi T; Wakasugi T; Ueda K
    Atherosclerosis; 1988 Aug; 72(2-3):183-8. PubMed ID: 3145745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition.
    Bard JM; Parra HJ; Douste-Blazy P; Fruchart JC
    Metabolism; 1990 Mar; 39(3):269-73. PubMed ID: 2106607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia.
    Franceschini G; Sirtori M; Vaccarino V; Gianfranceschi G; Chiesa G; Sirtori CR
    J Lab Clin Med; 1989 Sep; 114(3):250-9. PubMed ID: 2504855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of CS-514, a new inhibitor of HMG CoA reductase, on plasma lipids, lipoproteins and apoproteins in patients with primary hypercholesterolemia.
    Kazumi T; Yoshino G; Kasama T; Iwatani I; Iwai M; Morita S; Baba S
    Horm Metab Res; 1986 Sep; 18(9):654-5. PubMed ID: 3096862
    [No Abstract]   [Full Text] [Related]  

  • 7. The effect of CS-514 on serum lipids and apolipoproteins in hypercholesterolemic subjects.
    Nakaya N; Homma Y; Tamachi H; Shigematsu H; Hata Y; Goto Y
    JAMA; 1987 Jun; 257(22):3088-93. PubMed ID: 3108527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of nicotinic acid therapy on plasma lipoproteins and very low density lipoprotein apoprotein C subspecies in hyperlipoproteinemia.
    Yovos JG; Patel ST; Falko JM; Newman HA; Hill DS
    J Clin Endocrinol Metab; 1982 Jun; 54(6):1210-5. PubMed ID: 7076797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term treatment of hypercholesterolemic non-insulin dependent diabetics (NIDDM) with pravastatin (CS-514).
    Yoshino G; Kazumi T; Iwai M; Matsushita M; Matsuba K; Uenoyama R; Iwatani I; Baba S
    Atherosclerosis; 1989 Jan; 75(1):67-72. PubMed ID: 2495012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Change in very low-, low-, and high-density lipoproteins during lipid lowering (bezafibrate) therapy: studies in type IIA and type IIb hyperlipoproteinaemia.
    Gavish D; Oschry Y; Fainaru M; Eisenberg S
    Eur J Clin Invest; 1986 Feb; 16(1):61-8. PubMed ID: 3084275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic efficacy of the HMG-CoA-reductase inhibitor pravastatin in hyperlipoproteinaemia type II.
    Saxenhofer H; Weidmann P; Riesen WF; Beretta-Piccoli C; Fragiacomo C; Wunderlin R; Noseda G
    Eur J Clin Pharmacol; 1990; 39(2):101-5. PubMed ID: 2123791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemfibrozil therapy in primary type II hyperlipoproteinemia: effects on lipids, lipoproteins and apolipoproteins.
    Lupien PJ; Brun D; Gagné C; Moorjani S; Bielman P; Julien P
    Can J Cardiol; 1991; 7(1):27-33. PubMed ID: 2025787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of CS-514, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on lipoprotein and apolipoprotein in plasma of hypercholesterolemic diabetics.
    Yoshino G; Kazumi T; Kasama T; Iwatani I; Iwai M; Inui A; Otsuki M; Baba S
    Diabetes Res Clin Pract; 1986 Jun; 2(3):179-81. PubMed ID: 3091343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in plasma lipids, lipoproteins and apolipoproteins in hypercholesterolaemic patients treated with pravastatin.
    Lijnen P; Celis H; Desager JP; Fagard R
    J Hum Hypertens; 1995 Jul; 9(7):557-64. PubMed ID: 7562885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels.
    Alaupovic P; Heinonen T; Shurzinske L; Black DM
    Atherosclerosis; 1997 Aug; 133(1):123-33. PubMed ID: 9258416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of oxandrolone on plasma lipoproteins in patients with type IIa, IIb and IV hyperlipoproteinemia: occurrence of hypo-high density lipoproteinemia.
    Tamai T; Nakai T; Yamada S; Kobayashi T; Hayashi T; Kutsumi Y; Takeda R
    Artery; 1979 Feb; 5(2):125-43. PubMed ID: 231951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of combination therapy with estrogen plus simvastatin on lipoprotein metabolism in postmenopausal women with type IIa hypercholesterolemia.
    Wakatsuki A; Okatani Y; Ikenoue N
    Atherosclerosis; 2000 May; 150(1):103-11. PubMed ID: 10781640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of low-density lipoprotein receptors as estimated from concentrations of apolipoprotein B and C-II in serum.
    Ito H; Naito C; Hayashi H; Kawamura M
    Clin Chem; 1988 Nov; 34(11):2224-7. PubMed ID: 3141083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia.
    Mabuchi H; Haba T; Tatami R; Miyamoto S; Sakai Y; Wakasugi T; Watanabe A; Koizumi J; Takeda R
    N Engl J Med; 1981 Aug; 305(9):478-82. PubMed ID: 7254297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.